Cadonilimab (bispecific Anti-PD-1/CTLA-4 Antibody) for PD-1/PD-L1 Blockade-refractory, Microsatellite Instability-high (MSI-H) or Mismatch Repair-deficient (dMMR), Advanced Colorectal Cancer: a Single Group, Multicenter, Phase 2 Trial
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Cadonilimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 31 Aug 2022 Status changed from not yet recruiting to recruiting.
- 24 Jun 2022 New trial record